

Bengt I Eriksson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/906696/publications.pdf>

Version: 2024-02-01

66
papers

8,095
citations

172457

29
h-index

114465

63
g-index

66
all docs

66
docs citations

66
times ranked

3784
citing authors

#	ARTICLE	IF	CITATIONS
1	Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty. <i>New England Journal of Medicine</i> , 2008, 358, 2765-2775.	27.0	1,349
2	Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. <i>Lancet, The</i> , 2007, 370, 949-956.	13.7	1,077
3	Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. <i>Lancet, The</i> , 2008, 372, 31-39.	13.7	992
4	Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. <i>Lancet, The</i> , 2002, 359, 1721-1726.	13.7	466
5	Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development. <i>Clinical Pharmacokinetics</i> , 2009, 48, 1-22.	3.5	466
6	Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). <i>Thrombosis and Haemostasis</i> , 2011, 105, 721-729.	3.4	374
7	Duration of Prophylaxis Against Venous Thromboembolism With Fondaparinux After Hip Fracture Surgery_{title>A Multicenter, Randomized, Placebo-Controlled, Double-blind Study}. <i>Archives of Internal Medicine</i> , 2003, 163, 1337.	3.8	321
8	A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement. <i>Circulation</i> , 2006, 114, 2374-2381.	1.6	312
9	Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. <i>Lancet, The</i> , 2002, 360, 1441-1447.	13.7	263
10	Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. <i>Thrombosis and Haemostasis</i> , 2011, 105, 444-453.	3.4	250
11	Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. <i>Thrombosis and Haemostasis</i> , 2008, 100, 453-461.	3.4	242
12	Chordoma:<i>A Clinicopathologic and Prognostic Study of a Swedish National Series</i>. <i>Acta Orthopaedica</i> , 1981, 52, 49-58.	1.4	207
13	Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism. <i>Annual Review of Medicine</i> , 2011, 62, 41-57.	12.2	177
14	Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. <i>Thrombosis and Haemostasis</i> , 2010, 104, 642-649.	3.4	144
15	Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement. <i>Thrombosis Research</i> , 2007, 120, 685-693.	1.7	137
16	Transfusions and blood loss in total hip and knee arthroplasty: a prospective observational study. <i>Journal of Orthopaedic Surgery and Research</i> , 2015, 10, 48.	2.3	128
17	Surgical Predictors of Early Revision Surgery After Anterior Cruciate Ligament Reconstruction. <i>American Journal of Sports Medicine</i> , 2014, 42, 1574-1582.	4.2	106
18	Predictors of Clinical Outcome After Acute Achilles Tendon Ruptures. <i>American Journal of Sports Medicine</i> , 2014, 42, 1448-1455.	4.2	82

#	ARTICLE	IF	CITATIONS
19	Subacute versus delayed reconstruction of the anterior cruciate ligament in the competitive athlete. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , 1999, 7, 146-151.	4.2	77
20	Oral Anticoagulants in Development. <i>Drugs</i> , 2006, 66, 1411-1429.	10.9	73
21	Comparison between mixed and laminar airflow systems in operating rooms and the influence of human factors: Experiences from a Swedish orthopedic center. <i>American Journal of Infection Control</i> , 2014, 42, 665-669.	2.3	66
22	Thrombosis after hip replacement: Relationship to the fibrinolytic system. <i>Acta Orthopaedica</i> , 1989, 60, 159-163.	1.4	60
23	Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. <i>Thrombosis and Haemostasis</i> , 2003, 89, 288-96.	3.4	59
24	Kinematics after tear in the anterior cruciate ligament: Dynamic bilateral radiostereometric studies in 11 patients. <i>Acta Orthopaedica</i> , 2001, 72, 372-378.	1.4	58
25	Intraarticular morphine after arthroscopic ACL reconstruction: A double-blind placebo-controlled study of 40 patients. <i>Acta Orthopaedica</i> , 2000, 71, 280-285.	1.4	47
26	Sex Differences in Outcome After an Acute Achilles Tendon Rupture. <i>Orthopaedic Journal of Sports Medicine</i> , 2015, 3, 232596711558676.	1.7	47
27	Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. <i>Thrombosis Research</i> , 2012, 130, 147-151.	1.7	46
28	A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MELagatran for THRombin inhibition in Orthopaedic surgery. <i>Thrombosis and Haemostasis</i> , 2002, 87, 231-7.	3.4	34
29	Hand hygiene and aseptic techniques during routine anesthetic care - observations in the operating room. <i>Antimicrobial Resistance and Infection Control</i> , 2015, 4, 5.	4.1	32
30	Prevention of Venous Thromboembolism Following Orthopaedic Surgery. <i>Drugs</i> , 2004, 64, 577-595.	10.9	30
31	Is Colour Doppler Ultrasound a Sensitive Screening Method in Diagnosing Deep Vein Thrombosis after Hip Surgery ?. <i>Thrombosis and Haemostasis</i> , 1996, 75, 242-245.	3.4	29
32	Thromboprophylaxis with dabigatran etexilate in patients over seventy-five years of age with moderate renal impairment undergoing or knee replacement. <i>International Orthopaedics</i> , 2012, 36, 741-748.	1.9	24
33	Dabigatran Etexilate: Pivotal Trials for Venous Thromboembolism Prophylaxis After Hip or Knee Arthroplasty. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 25S-31S.	1.7	23
34	Performance Enhancement following a Strength and Injury Prevention Program: A 26-Week Individualized and Supervised Intervention in Adolescent Female Volleyball Players. <i>International Journal of Sports Science and Coaching</i> , 2011, 6, 399-417.	1.4	23
35	Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials. <i>Thrombosis Journal</i> , 2015, 13, 36.	2.1	22
36	Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 171-182.	1.7	20

#	ARTICLE	IF	CITATIONS
37	A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding. <i>Blood</i> , 2008, 112, 36-36.	1.4	20
38	Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: A pooled analysis. <i>Thrombosis Research</i> , 2012, 130, 818-820.	1.7	19
39	Preoperative plasma fibrinogen concentration, factor XIII activity, perioperative bleeding, and transfusions in elective orthopaedic surgery: A prospective observational study. <i>Thrombosis Research</i> , 2016, 139, 142-147.	1.7	18
40	Nucleostemin- and Oct 3/4-positive stem/progenitor cells exhibit disparate anatomical and temporal expression during rat Achilles tendon healing. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 212.	1.9	17
41	Efficacy and Safety Profile of Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Moderately Renally Impaired Patients after Total Knee or Hip Replacement Surgery.. <i>Blood</i> , 2008, 112, 981-981.	1.4	17
42	Detection of slow-cycling and stem/progenitor cells in different regions of rat Achilles tendon: response to treadmill exercise. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , 2013, 21, 1694-1703.	4.2	16
43	Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement. <i>Thrombosis Research</i> , 2002, 105, 371-378.	1.7	15
44	Extended Thromboprophylaxis with Rivaroxaban Compared with Short-Term Thromboprophylaxis with Enoxaparin after Total Hip Arthroplasty: The RECORD2 Trial.. <i>Blood</i> , 2007, 110, 307-307.	1.4	13
45	Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3). <i>Thrombosis and Haemostasis</i> , 2014, 111, 213-225.	3.4	12
46	Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis after Total Hip Arthroplasty: The RECORD1 Trial.. <i>Blood</i> , 2007, 110, 6-6.	1.4	12
47	Efficacy and Safety Profile of Dabigatran Etexilate Compared with Enoxaparin in Primary Venous Thromboembolism Prevention after Total Knee or Hip Replacement Surgery in Patients Over 75 Years. <i>Blood</i> , 2008, 112, 437-437.	1.4	9
48	Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.. <i>Blood</i> , 2005, 106, 280-280.	1.4	7
49	A man with presumptive Y/Y translocation, observed in a forensic psychiatric department. <i>Clinical Genetics</i> , 1976, 10, 82-88.	2.0	6
50	Efficacy of delayed thromboprophylaxis with dabigatran: Pooled analysis. <i>Thrombosis Research</i> , 2012, 130, 871-876.	1.7	6
51	Complete mid-portion rupture of the rat achilles tendon leads to remote and time-mismatched changes in uninjured regions. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , 2021, 29, 1990-1999.	4.2	6
52	Ximelagatran in Orthopaedic Surgery. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2005, 34, 10-17.	0.3	5
53	Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.. <i>Blood</i> , 2006, 108, 903-903.	1.4	5
54	Phase II Dose-Finding Study with TAK-442, An Oral Factor Xa Inhibitor, in Patients Undergoing Elective Knee Arthroplasty.. <i>Blood</i> , 2009, 114, 170-170.	1.4	5

#	ARTICLE	IF	CITATIONS
55	Clinical Experience with Ximelagatran in Orthopaedic Surgery. <i>Drugs</i> , 2004, 64, 27-35.	10.9	4
56	An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150 mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery. <i>Thrombosis Research</i> , 2016, 144, 158-164.	1.7	4
57	A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications.. <i>Blood</i> , 2008, 112, 1986-1986.	1.4	4
58	Improvements in the prevention of postoperative venous thromboembolism in hip fracture patients. <i>Orthopedics</i> , 2003, 26, s851-8.	1.1	4
59	Thromboprophylaxis after Orthopaedic Surgery with an Oral, Direct Factor Xa Inhibitor: Pooled Results of Two Phase I/II Clinical Trials.. <i>Blood</i> , 2005, 106, 277-277.	1.4	3
60	Survival in patients undergoing total hip arthroplasty in relation to thromboprophylaxis with low molecular weight heparin: a long-term follow-up study. <i>International Journal of Risk and Safety in Medicine</i> , 1996, 8, 251-259.	0.6	2
61	VENUS - A Study To Validate Centrally Adjudicated Venous Ultrasound Against Venography after Major Orthopaedic Surgery.. <i>Blood</i> , 2005, 106, 281-281.	1.4	1
62	Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban.. <i>Blood</i> , 2009, 114, 2099-2099.	1.4	1
63	Oral Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty: A Pooled Analysis of Four Randomized Trials. <i>Blood</i> , 2011, 118, 2312-2312.	1.4	1
64	Location of postoperative deep vein thrombosis in relation to age and survival. <i>International Journal of Risk and Safety in Medicine</i> , 1997, 10, 229-234.	0.6	0
65	Validation of the HEMOCLOTÂ® Direct Thrombin Inhibitor Assay for Dabigatran by Comparison with a Validated LC-MS/MS Method in Plasma Samples From Patients After Major Orthopaedic Surgery. <i>Blood</i> , 2011, 118, 2307-2307.	1.4	0
66	Evaluation of the Acute Coronary Syndrome Safety Profile of Dabigatran Etexilate in Patients Undergoing Major Orthopaedic Surgery: Findings From Four Phase III Trials. <i>Blood</i> , 2011, 118, 2309-2309.	1.4	0